Assessment of the in vitro Efficacy of the Novel Antimicrobial Peptide CECT7121 against Human Gram-Positive Bacteria from Serious Infections Refractory to Treatment

作者：Sparo M D; Jones D G; Sanchez Bruni S F

来源：Chemotherapy, 2009, 55(4): 270-277.

DOI：10.1159/000223069

• AP-CECT7121
• Bacterial resistance
• Enterococcus spp.
• Gram-positive bacteria
• Staphylococci
• Streptococci

Background: Resistant Gram-positive bacteria are causing increasing concern in clinical practice. This work investigated the efficacy of AP-CECT7121 (an antimicrobial peptide isolated from an environmental strain of Enterococcus faecalis CECT7121) against various pathogenic Gram-positive bacteria. Methods: Strains were isolated from intensive care unit patients unresponsive to standard antibiotic treatments. Inhibitory activity of AP-CECT7121 was assessed using the agar-well diffusion method. The most resistant isolates from each species screened (Enterococcus faecium, Enterococcus faecalis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Clostridium perfringens and Clostridium difficile) were further examined in time-killing curve studies. Results: These bactericidal kinetic experiments demonstrated a rapid killing effect with no viable bacteria being detected within 30 and 90 min for enterococcal and streptococcal strains and 180 min for community-acquired methicillin-resistant S. aureus and C. perfringens : viable counts for C. difficile were threefold decreased after 90 min. Conclusions: AP-CECT7121 may provide a novel strategy for treating potentially fatal clinical infections in hospitalized patients.

• 出版日期2009